奥希替尼靶向治疗晚期非小细胞肺癌临床研究  

Clinical Study of Osimertinib Targeted Therapy for Advanced Non-Small Cell Lung Cancer

作　　者：李泞甫 陈旭澜 曾蓓蕾 皈燕[1,2] LI Ningfu;CHEN Xulan;ZENG Beilei;GUI Yan(North Sichuan Medical College,Nanchong,Sichuan,China 637000;The Affiliated Hospital of North Sichuan Medical College,Nanchong,Sichuan,China 637000)

机构地区：[1]川北医学院,四川南充637000 [2]川北医学院附属医院,四川南充637000

出　　处：《中国药业》2024年第10期101-103,共3页China Pharmaceuticals

基　　金：四川省自然科学基金[2022NSFSC1554]。

摘　　要：目的探讨奥希替尼靶向治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取医院肿瘤科2021年1月至2022年12月收治的晚期NSCLC患者113例,根据治疗方案的不同分为化学药物治疗(简称化疗)组(54例)和靶向治疗(简称靶向)组(59例)。化疗组患者予注射用培美曲塞二钠+注射用顺铂静脉滴注,靶向组患者口服甲磺酸奥希替尼片。结果靶向组疾病控制率为93.22%,显著高于化疗组的74.07%(P<0.05)。两组患者治疗后的血清癌胚抗原、鳞状上皮细胞癌抗原、细胞角蛋白19片段抗原21-1水平均显著降低(P<0.05),且靶向组患者改善幅度显著大于化疗组(P<0.05)。靶向组患者治疗后的T淋巴细胞亚群CD_(4)^(+)水平显著升高,CD_(8)^(+)水平显著降低,CD_(4)^(+)/CD_(8)^(+)显著升高(P<0.05)。靶向组不良反应发生率为11.86%,显著低于化疗组的29.63%(P<0.05)。结论奥希替尼靶向治疗晚期NSCLC,可降低患者的血清肿瘤细胞因子水平,且对免疫功能影响轻微。Objective To investigate the clinical efficacy of osimertinib targeted therapy for advanced non-small cell lung cancer(NSCLC).Methods A total of 113 patients with advanced NSCLC admitted to the oncology department of the hospital from January 2021 to December 2022 were selected and divided into the chemotherapy group(54 cases)and the targeted therapy group(referred to as the targeted group,59 cases)based on different treatment regimens.The patients in the chemotherapy group were given intravenous drip of Pemetrexed Disodium for Injection+Cisplatin for Injection,while the patients in the targeted group were given Osimertinib Mesylate Tablets orally.Results The disease control rate in the targeted group was 93.22%,which was significantly higher than 74.07%in the chemotherapy group(P<0.05).After treatment,the serum carcinoembryonic antigen(CEA),squamous cell carcinoma-antigen(SCC-Ag)and cytokeratin 19 fragment antigen 21-1(CYFRA21-1)levels in the two groups were significantly lower(P<0.05),and those in the targeted group were significantly better(P<0.05).After treatment,the T lymphocyte subgroup CD_(4)^(+)level in the targeted group was significantly higher,the CD_(8)^(+)level was significantly lower,and the CD_(4)^(+)/CD_(8)^(+)was significantly higher(P<0.05).The incidence of adverse reactions in the targeted group was 11.86%,which was significantly lower than 29.63%in the chemotherapy group(P<0.05).Conclusion Osimertinib targeted therapy can decrease the serum tumor cytokine level in patients with advanced NSCLC and has a slight effect on their immune function.

关 键 词：奥希替尼 靶向治疗 晚期 非小细胞肺癌 肿瘤细胞因子 免疫功能 临床疗效 

分 类 号：R979.14[医药卫生—药品]